Converting potent indeno[1,2-b]indole inhibitors of protein kinase CK2 into selective inhibitors of the breast cancer resistance protein ABCG2.

A series of indeno[1,2-b]indole-9,10-dione derivatives were synthesized as human casein kinase II (CK2) inhibitors. The most potent inhibitors contained a N(5)-isopropyl substituent on the C-ring. The same series of compounds was found to also inhibit the breast cancer resistance protein ABCG2 but with totally different structure-activity relationships: a N(5)-phenethyl substituent was critical, and additional hydrophobic substituents at position 7 or 8 of the D-ring or a methoxy at phenethyl position ortho or meta also contributed to inhibition. The best ABCG2 inhibitors, such as 4c, 4h, 4i, 4j, and 4k, behaved as very weak inhibitors of CK2, whereas the most potent CK2 inhibitors, such as 4a, 4p, and 4e, displayed limited interaction with ABCG2. It was therefore possible to convert, through suitable substitutions of the indeno[1,2-b]indole-9,10-dione scaffold, potent CK2 inhibitors into selective ABCG2 inhibitors and vice versa. In addition, some of the best ABCG2 inhibitors, which displayed a very low cytotoxicity, thus giving a high therapeutic ratio, and appeared not to be transported, constitute promising candidates for further investigations.

[1]  N. Taylor,et al.  Total synthesis of isoprekinamycin: structural evidence for enhanced diazonium ion character and growth inhibitory activity toward cancer cells. , 2007, Organic letters.

[2]  L. Pinna,et al.  Structural and functional analysis of the flexible regions of the catalytic α-subunit of protein kinase CK2. , 2012, Journal of structural biology.

[3]  G. Szakács,et al.  Structure-activity relationships of chromone derivatives toward the mechanism of interaction with and inhibition of breast cancer resistance protein ABCG2. , 2013, Journal of medicinal chemistry.

[4]  S. Bates,et al.  Comparison of ATP-Binding Cassette Transporter Interactions with the Tyrosine Kinase Inhibitors Imatinib, Nilotinib, and Dasatinib , 2010, Drug Metabolism and Disposition.

[5]  F. Totzke,et al.  Indeno[1,2-b]indole derivatives as a novel class of potent human protein kinase CK2 inhibitors. , 2012, Bioorganic & medicinal chemistry.

[6]  R. Prudent,et al.  Structure-based discovery of small molecules targeting different surfaces of protein-kinase CK2. , 2010, Biochimica et biophysica acta.

[7]  P. Houghton,et al.  Imatinib Mesylate Is a Potent Inhibitor of the ABCG2 (BCRP) Transporter and Reverses Resistance to Topotecan and SN-38 in Vitro , 2004, Cancer Research.

[8]  F. Zhou,et al.  Casein kinase 2 inhibition attenuates androgen receptor function and cell proliferation in prostate cancer cells , 2012, The Prostate.

[9]  Fu-Yuan Tsai,et al.  In Silico Prediction of Inhibition of Promiscuous Breast Cancer Resistance Protein (BCRP/ABCG2) , 2014, PloS one.

[10]  I. Catalá,et al.  Frequent expression of the multi‐drug resistance‐associated protein BCRP/MXR/ABCP/ABCG2 in human tumours detected by the BXP‐21 monoclonal antibody in paraffin‐embedded material , 2002, The Journal of pathology.

[11]  N. Oleinick,et al.  Staurosporine-induced death of MCF-7 human breast cancer cells: a distinction between caspase-3-dependent steps of apoptosis and the critical lethal lesions. , 2003, Experimental cell research.

[12]  E. P. Kennedy,et al.  The enzymatic phosphorylation of proteins. , 1954, The Journal of biological chemistry.

[13]  Ulf Norinder,et al.  A Global Drug Inhibition Pattern for the Human ATP-Binding Cassette Transporter Breast Cancer Resistance Protein (ABCG2) , 2007, Journal of Pharmacology and Experimental Therapeutics.

[14]  A. di Pietro,et al.  ABCG2: recent discovery of potent and highly selective inhibitors. , 2013, Future medicinal chemistry.

[15]  Christin Müller,et al.  Potent and selective inhibitors of breast cancer resistance protein (ABCG2) derived from the p-glycoprotein (ABCB1) modulator tariquidar. , 2009, Journal of medicinal chemistry.

[16]  S. Bates,et al.  Linsitinib (OSI-906) antagonizes ATP-binding cassette subfamily G member 2 and subfamily C member 10-mediated drug resistance. , 2014, The international journal of biochemistry & cell biology.

[17]  T. Pawson,et al.  Identification of a Novel Protein Interaction Motif in the Regulatory Subunit of Casein Kinase 2 , 2013, Molecular and Cellular Biology.

[18]  M. Ychou,et al.  Sorafenib Overcomes Irinotecan Resistance in Colorectal Cancer by Inhibiting the ABCG2 Drug-Efflux Pump , 2013, Molecular Cancer Therapeutics.

[19]  O. Issinger,et al.  Isolation and characterization of recombinant human casein kinase II subunits α and β from bacteria , 1991 .

[20]  O. Issinger,et al.  First structure of protein kinase CK2 catalytic subunit with an effective CK2β-competitive ligand. , 2013, ACS chemical biology.

[21]  L. Galluzzi,et al.  Erlotinib antagonizes ABC transporters in acute myeloid leukemia , 2012, Cell cycle.

[22]  G. Kéri,et al.  High-affinity interaction of tyrosine kinase inhibitors with the ABCG2 multidrug transporter. , 2004, Molecular pharmacology.

[23]  S H Kaufmann,et al.  The HER tyrosine kinase inhibitor CI1033 enhances cytotoxicity of 7-ethyl-10-hydroxycamptothecin and topotecan by inhibiting breast cancer resistance protein-mediated drug efflux. , 2001, Cancer research.

[24]  M. Sainsbury,et al.  The Coupling Reactions of 3-Acylindoles and Proof of Structure of the Palladium (II) Acetane Mediated Cyclisation Reaction Product of 3-Benzoyl-1-methylindole , 1983 .

[25]  P. L. Ee,et al.  Dimethoxyaurones: Potent inhibitors of ABCG2 (breast cancer resistance protein). , 2008, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[26]  C. Götz,et al.  A CE‐based assay for human protein kinase CK2 activity measurement and inhibitor screening , 2010, Electrophoresis.

[27]  I. Bilbao-Meseguer,et al.  Drug interactions with sunitinib , 2015, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.

[28]  S. Bates,et al.  Inhibition of ABCG2-mediated transport by protein kinase inhibitors with a bisindolylmaleimide or indolocarbazole structure , 2007, Molecular Cancer Therapeutics.

[29]  K. Matsuo,et al.  Synthesis of murrayaquinone-A. , 1994, Chemical & pharmaceutical bulletin.

[30]  A. Buschauer,et al.  Solid phase synthesis of tariquidar-related modulators of ABC transporters preferring breast cancer resistance protein (ABCG2). , 2011, Bioorganic & medicinal chemistry letters.

[31]  J. Dagorn,et al.  A Review of Kinases Implicated in Pancreatic Cancer , 2010, Pancreatology.

[32]  F. Totzke,et al.  Novel indeno[1,2-b]indoloquinones as inhibitors of the human protein kinase CK2 with antiproliferative activity towards a broad panel of cancer cell lines. , 2012, Biochemical and biophysical research communications.

[33]  H. G. Richey,et al.  Sulfamides and sulfonamides as polar aprotic solvents , 1987 .

[34]  Veerababurao Kavala,et al.  An Easy Access to Carbazolones and 2,3-Disubstituted Indoles , 2011 .

[35]  D. Birnbaum,et al.  Protein kinase CK2α subunit over-expression correlates with metastatic risk in breast carcinomas: quantitative immunohistochemistry in tissue microarrays. , 2011, European journal of cancer.

[36]  G. Reiss,et al.  Partially Saturated Indeno[1,2-b]indole Derivatives via Deoxygenationof Heterocyclic α-Hydroxy-N,O-hemiaminals , 2009 .

[37]  J. Jose,et al.  Synthesis and biological evaluation of novel substituted pyrrolo[1,2-a]quinoxaline derivatives as inhibitors of the human protein kinase CK2. , 2013, European journal of medicinal chemistry.

[38]  Joachim Jose,et al.  Synthesis and Biological Evaluation of 3-(Substituted-benzylidene)-1,3-dihydro-indolin Derivatives as Human Protein Kinase CK2 and p60c-Src Tyrosine Kinase Inhibitors , 2007 .

[39]  G. Sheldrick A short history of SHELX. , 2008, Acta crystallographica. Section A, Foundations of crystallography.

[40]  M. Hawkins,et al.  Bryostatin-I—An Antineoplastic Treasure from the Deep? , 2002, Cancer biology & therapy.

[41]  G. K. Gray,et al.  Therapeutic CK2 inhibition attenuates diverse prosurvival signaling cascades and decreases cell viability in human breast cancer cells , 2014, Oncotarget.

[42]  J. Schellens,et al.  Potent and specific inhibition of the breast cancer resistance protein multidrug transporter in vitro and in mouse intestine by a novel analogue of fumitremorgin C. , 2002, Molecular cancer therapeutics.

[43]  A. Goffeau,et al.  Protein kinase C effectors bind to multidrug ABC transporters and inhibit their activity. , 2001, Biochemistry.

[44]  Timothy J. Mitchison,et al.  A chemical method for fast and sensitive detection of DNA synthesis in vivo , 2008, Proceedings of the National Academy of Sciences.

[45]  D. Richardson,et al.  Molecular Pharmacology of ABCG2 and Its Role in Chemoresistance , 2013, Molecular Pharmacology.

[46]  G. Szakács,et al.  Interaction of the EGFR inhibitors gefitinib, vandetanib, pelitinib and neratinib with the ABCG2 multidrug transporter: implications for the emergence and reversal of cancer drug resistance. , 2012, Biochemical pharmacology.

[47]  T. Kinoshita,et al.  Crystal structure of human CK2α at 1.06 Å resolution , 2013, Journal of synchrotron radiation.

[48]  H. Willard,et al.  Recent developments in the detection of deoxyribonucleic acid synthesis by 33258 Hoechst fluorescence. , 1975, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[49]  M. Bredel,et al.  Targeting Protein Kinase CK2 Suppresses Prosurvival Signaling Pathways and Growth of Glioblastoma , 2013, Clinical Cancer Research.

[50]  Min Zhao,et al.  Inhibition of CK2 enhances UV-triggered apoptotic cell death in lung cancer cell lines. , 2013, Oncology reports.

[51]  T. Mosmann Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. , 1983, Journal of immunological methods.

[52]  L. Cesaro,et al.  Aberrant signalling by protein kinase CK2 in imatinib‐resistant chronic myeloid leukaemia cells: Biochemical evidence and therapeutic perspectives , 2013, Molecular oncology.

[53]  Y. Sugimoto,et al.  Gefitinib reverses breast cancer resistance protein-mediated drug resistance. , 2004, Molecular cancer therapeutics.